The present invention provides beverages and pharmaceutical compositions containing a deuterated alcohol according to Formula 1, and provides methods for their manufacture and use.

##STR00001##

The compositions of the invention are expected to ameliorate some of the negative side effects associated with the consumption of alcohol, such as hangover and facial flushing.

Provided are a compound for alcoholic liver injury, a preparation method, a composition, a food and the use. The compound has the following formula (I), wherein M is a divalent metal cation selected from Cu, Fe and Zn; A is selected from glutathione and a derivative thereof, and the derivative of glutathione is selected from: at least one of amino or carboxyl in glutathione substituted with an amino protecting group and/or a carboxyl protecting group; B is a monovalent or divalent balance anion; and n is 1 or 2.

[M(A).sub.2].Math.nB(I)

Provided are a compound for alcoholic liver injury, a preparation method, a composition, a food and the use. The compound has the following formula (I), wherein M is a divalent metal cation selected from Cu, Fe and Zn; A is selected from glutathione and a derivative thereof, and the derivative of glutathione is selected from: at least one of amino or carboxyl in glutathione substituted with an amino protecting group and/or a carboxyl protecting group; B is a monovalent or divalent balance anion; and n is 1 or 2.

[M(A).sub.2].Math.nB(I)

The present invention provides beverages and pharmaceutical compositions containing a deuterated alcohol according to Formula 1, and provides methods for their manufacture and use. ##STR00001##
The compositions of the invention are expected to ameliorate some of the negative side effects associated with the consumption of alcohol, such as hangover and facial flushing.

The present invention provides beverages and pharmaceutical compositions containing a deuterated alcohol according to Formula 1, and provides methods for their manufacture and use.

##STR00001##

The compositions of the invention are expected to ameliorate some of the negative side effects associated with the consumption of alcohol, such as hangover and facial flushing.

Provided herein are products for consumers comprising a greater than naturally-occurring amount of deuterium oxide.

Provided herein are products for consumers comprising a greater than naturally-occurring amount of deuterium oxide.

A method for preparing ethanol-containing nanolipid particles, which can be used in food products, frozen desserts, or beverages. The method comprises nanolipidic vehicles in which ethanol-containing substances are encapsulated, said ethanol-containing nanolipidic vehicles can be combined with food products, desserts or beverage ingredients including those that are subsequently frozen. The food product, dessert or beverage can remain in a frozen state during consumption by an individual. A composition comprising ethanol-containing nanolipid particles, which can be used in food products, frozen desserts, or beverages.

A method for preparing ethanol-containing nanolipid particles, which can be used in food products, frozen desserts, or beverages. The method comprises nanolipidic vehicles in which ethanol-containing substances are encapsulated, said ethanol-containing nanolipidic vehicles can be combined with food products, desserts or beverage ingredients including those that are subsequently frozen. The food product, dessert or beverage can remain in a frozen state during consumption by an individual. A composition comprising ethanol-containing nanolipid particles, which can be used in food products, frozen desserts, or beverages.

Provided is a pharmaceutical composition for preventing, improving, or treating postmenopausal osteoporosis in women, the composition including, as an active ingredient, scopolin, a derivative thereof, or a pharmaceutically acceptable salt thereof, wherein scopolin has good efficacy in stimulating osteoblast differentiation, and is also effective in inhibiting a reduction in bone density after menopause, low density in a bone microstructure, a reduction in a bone formation marker in the blood, and an increase in a bone resorption marker. Therefore, scopolin and the composition including the same as an active ingredient are expected to be useful as pharmaceutical preparations for the prevention, improvement, or treatment of postmenopausal osteoporosis in women.